A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

This prospective, multicenter, single-arm phase II trial aims to evaluate the clinical efficacy and safety of the combination therapy of Disitamab Vedotin with Tislelizumab and a second transurethral resection for the treatment of high-risk, very high-risk NMIBC with HER2 2+-3+.

NCT Number	NCT06630871
Lead Sponsor	Fujian Medical University Union Hospital Collaborators: BeiGene, RemeGen Co., Ltd.
Conditions	NMIBC
Enrollment	40 participants
Start Date	2024-10
Primary Completion	2026-10 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2024-10-10